Healthcare is a high-value industry, but powerful trends are creating urgent needs and driving further growth.
The dominant trend is societal; a growing global population with increased life-expectancy – the so called ‘ageing ailing’ population. On its own this trend creates the need for better therapies, or for new ones such as immunotherapy or cell therapy.
But this societal trend is also creating an economic trend - an unmanageable and unsustainable increase in the cost of care. The need is not just for better therapies, but for better value; so-called value-based healthcare.
Healthcare providers are increasingly focused on the total cost of care, driving the shift in care setting from hospital to home, amongst other things. And those providers offering products and services – the pharmaceutical, biotechnology, and medical device companies – are under ever-increasing pressure to generate the clinical and economic evidence to support the value and price of their goods.
Among many other themes, this is affecting clinical trials' design, creating a need for personalised medicine or companion diagnostics, and driving interest in areas such as patient adherence, biosensors and telemetry, and digital products and services.
Addressing the need and creating the value
Sensing with biomimetic glucose binding molecules
CoVent – TTP’s rapid manufacture ventilator for COVID-19 patients
TTP fast-tracks development of world’s first DNA-based service for personalised lifestyle recommendations
TTP designs commercial-ready applicator for 3M’s hollow microneedle array
Puckdx™: TTP’s robot in a coffee pod
Amplifying DNA as fast as the biology permits
Cyto-Mine® Single Cell Analysis System
Well Cow: monitoring the gut health of dairy cows with an ingestible bolus
eFlow®: A life-changing inhaler
We work at the intersection of physics, engineering and the biological sciences, creating and developing new technology for the life science industry.
Pharmaceutical companies face substantial challenges, from constraints in health spending to weakening drug pipelines. Yet opportunities exist for those bold enough to adapt, ranging from connected devices that drive adherence to generic devices at cost points previously thought impossible.
Disruptive change is rolling through the medical device industry as value-based healthcare and digitisation spread from niches to the mainstream. This is a challenging time, but it presents real opportunities for those ambitious companies prepared to reinvent themselves.
The diagnostic market is at a moment of change. New approaches, such as sequencing, are gaining traction; companion diagnostics are driving closer integration with therapy; continuous monitoring is enabling new diagnostic information; and market drivers are demanding low cost distribution of clinical quality data.
Human therapies are adapting to tackle increasingly complex immunological diseases and conditions. These therapies often rely on tightly controlled cell cultures in order to produce therapeutic drugs efficiently, such as monoclonal antibodies or culture of the patient’s own genetically-engineered cells, as part of an autologous cell therapy workflow.
Emerging biosensor technologies are enabling the measurement and analysis of valuable trace markers, leading to improved clinical outcomes by allowing the accurate observation of previously undetectable physiological signals in real time.
Increasing numbers of people are suffering from chronic conditions. Through the creation of tiny, fully integrated real-time measurement systems, smart implants are bringing the benefits of laboratory-grade telemetry to their lives.
As with other industries, digital technology is touching every aspect of healthcare. But health is unique in its complexity, and innovation requires deep insight.
Medical imaging is required to meet the needs of advanced diagnostics and the demands of emerging markets, presenting the sector with sizeable rewards for innovation.
Surgery is a fertile area for medical device innovation with remarkable developments occurring in minimally invasive and robotic assisted techniques. The future of the operating room relies on intraoperative technologies which improve clinical and economic values as measured by procedure outcome, workflow efficiency and patient safety.
Cell and Gene Therapies can cure the incurable. With more than a decade of experience, TTP works in partnership with companies to solve the challenges of these complex therapies. Together we will improve patient access and save lives.
Neurotechnology promises to revolutionise the treatment of a wide range of diseases. Improving outcomes for patients depends on bringing together an understanding of the pathology with the medical device hardware needed to physically interface with the nervous system.
Get in touch
Want to talk to us about healthcare?